CSL Limited (CMXHF)
OTCMKTS · Delayed Price · Currency is USD
121.49
+6.98 (6.10%)
Oct 31, 2025, 4:00 PM EDT
CSL Limited Revenue
In the fiscal year ending June 30, 2025, CSL Limited had annual revenue of $15.56B with 5.12% growth. CSL Limited had revenue of $7.08B in the half year ending June 30, 2025, with 15.49% growth.
Revenue
15.56B
Revenue Growth
+5.12%
P/S Ratio
3.63
Revenue / Employee
520.26K
Employees
29,904
Market Cap
56.40B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 15.56B | 758.00M | 5.12% |
| Jun 30, 2024 | 14.80B | 1.49B | 11.19% |
| Jun 30, 2023 | 13.31B | 2.75B | 26.02% |
| Jun 30, 2022 | 10.56B | 252.00M | 2.44% |
| Jun 30, 2021 | 10.31B | 1.16B | 12.67% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Jushi Holdings | 256.36M |
| Glass House Brands | 221.55M |
| Elite Pharmaceuticals | 105.45M |
| Silence Therapeutics | 27.17M |
| China New Energy Group Co. | 12.51M |
| Northwest Biotherapeutics | 1.09M |
CSL Limited News
- 5 days ago - CSL Limited (CSLLY) Shareholder/Analyst Call Transcript - Seeking Alpha
- 6 days ago - CSL Limited (CSLLY) Shareholder/Analyst Call - Slideshow - Seeking Alpha
- 7 days ago - CSL Honoured as Overall Winner of the 2025 Facility of the Year Awards by the International Society for Pharmaceutical Engineering (ISPE) - PRNewsWire
- 12 days ago - Recent RWE Data Show Cell-Based Influenza Vaccines Offer 20% Greater Protection in the Prevention of Test-Confirmed Influenza in Pediatric and Adult Populations Relative to Standard Egg-Based Influenza Vaccines - PRNewsWire
- 27 days ago - My Top 5 Biotech Stocks Big Pharma Could Buy Next - Seeking Alpha
- 27 days ago - CSL Behring Canada Signs LOI With PCPA For Public Reimbursement Of HEMGENIX - Nasdaq
- 2 months ago - CSL Limited falls as layoffs overshadow FY25 results - Seeking Alpha
- 2 months ago - CSL Limited (CSLLY) Q4 2025 Earnings Call Transcript - Seeking Alpha